News Warning letter adds to Applied Tx run of bad news Applied Therapeutics gets a warning letter from the FDA over a trial of rare disease drug govorestat, which was rejected by the agency last week.
News Applied Tx craters as FDA rejects lead product candidate Applied Therapeutics plummets after the FDA turns down its marketing application for govorestat as a treatment for galactosaemia
News Applied Therapeutics slumps as FDA seeks more data on lead d... Shares in Applied Therapeutics slumped today after it said it would have to delay a US filing for its lead drug programme AT-007, following an FDA request for more data.
Market Access The changing landscape of drug clinical assessment: Tommy Br... In a new pharmaphorum podcast, Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discusses Joint Clinical Assessments.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face